Our leadership team, including recognized physician experts and researchers, is at the forefront of shaping new standards of cancer care based upon the latest research. Patients are at the heart of everything we do. Sarah Cannon offers integrated cancer services, providing patients with cutting-edge treatments and upholding the highest quality care for patients from diagnosis through survivorship.
Gregg Fromell, MD
Vice President and Clinical Director at HCA Research Institute
Gregg Fromell, MD is Vice President and Clinical Director of the HCA Research Institute (HRI). The HRI is an extension of the Sarah Cannon Research Institute, and was created to support medical research in non-cancer conditions and diseases.The HRI is dedicated to the mission of supporting HCA Service Lines in their goals to improve the healthcare of our patients through scientific discovery.
Dr. Fromell is a clinician scientist who is passionate about clinical research and the translation of science into improvements in medical care. His research and management experience provides a vantage point that spans academia and industry, including roles as an academic clinical investigator at the University of Pennsylvania, research director in the pharmaceutical industry overseeing global multi-site studies, and an executive overseeing science operations, infrastructure, regulatory compliance, and research protections at a large academic health center, the NYU School of Medicine and Medical Center. Dr. Fromell’s 25-year career in clinical research provides medical, research, regulatory, and industry experience and perspective to the work of implementing the necessary infrastructure, resources, and safeguards to support the HCA research enterprise.